Trial | NCT00130429  Report issue

Title

Safety and Effect on Memory of PYM50028 in Mild Alzheimer's Disease
Phase II Randomised, Double Blind, Placebo Controlled, Parallel Group Study to Investigate the Safety, Effect on Cognition and Pharmacokinetic Profile of PYM50028 in Subjects With Mild Dementia of the Alzheimer's Type

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    pym50028 ...

  • Study Participants

    250
The purpose of this study is to assess the effect of PYM50028 administered once daily for up to 12 weeks on the memory and other faculties of subjects with dementia due to Alzheimer's disease.
Study Started
Jan 31
2004
Study Completion
Sep 30
2005
Last Update
Aug 21
2009
Estimate

Drug PYM50028

Criteria 

Inclusion Criteria:

At least 50 years of age
Diagnosis of possible or probable Alzheimer's disease
Mini mental state examination score at least 16
Good understanding of both written and verbal English
A recent head scan that is consistent with the diagnosis of Alzheimer's disease

Exclusion Criteria:

Recent history or clinical evidence of significant neurological disease other than dementia due to Alzheimer's disease
Known to have another condition that is associated with dementia
Use of psychotropic medication within the previous 4 weeks (excluding cholinesterase inhibitors, selective serotonin reuptake inhibitors and venlafaxine)
Hormone replacement therapy started or changed within the previous 6 months
Received any investigational drugs within the previous 12 weeks
No Results Posted